<p>The global recognition of azole resistance in fungal infection is steadily increasing and is perceived as a serious health threat, particularly among immunocompromised individuals. The rise in resistance is governed by multifactorial mechanisms including mutations in <i>ERG11/CYP5A</i>, overexpression of efflux transporters, and biofilm formation which enables pathogenic fungi to evade azole's antifungal activity. Most of the conducted work currently examines distinct processes without relating them to the broader issue, such as therapy inadequacies and diagnostic challenges, even though azole resistance continues to rise in clinical relevance. This review is focused on addressing this gap by providing comprehensive information into one framework for azole resistance. It presents the molecular basis of resistance, highlighting mechanisms such as target enzyme modification, efflux pump overexpression, biofilm-mediated protection, and transcriptional regulation of various fungal pathogens with an emphasis on <i>Candida</i> species. Also, we critically evaluated the strengths and limitations of currently used diagnostic platforms and explored therapeutic strategies, including novel antifungal agents, drug repurposing, immunotherapy, antifungal peptides, and stewardship models. Along with the long-established methods for combating the fungal infections, it also maneuvers through the contemporary approaches of omics and sophisticated bioinformatics tools employed in fungal research. By bridging the mechanistic insights with clinical and ecological relevance, this review aims to shed light on the development of precision diagnostics, novel antifungal targets, and integrative policy approaches to mitigate resistance and improve patient outcomes. Along with it, the article also traverses through the development of fourth generation azoles in combating fungal invasion.</p>